Eloralintide >99%

Eloralintide

Eloralintide;AMY1176;LY3841136;Eloralintide,LY3841136

2883634-40-8

0

262-076-3

White to off-white

Hormones and the Endocrine System

Amylin receptor (AMYR) agonist (peptide, long-acting)

Investigational — Phase 1/2 (T2DM and obesity)

Eloralintide is an amylin receptor agonist developed by Eli Lilly for type 2 diabetes and obesity. It activates the amylin receptor (AMYR), reducing food intake, delaying gastric emptying, and promoting satiety. It is structurally distinct from cagrilintide (Novo Nordisk). Being explored as monotherapy and in combination with GLP-1R agonists.

Limited public data. Eloralintide is in early clinical development; specific EC50 values have not been publicly disclosed.

MCE: Eloralintide (CAS 2883634-40-8); AbMole product data sheet.

PubChem

MCE: Eloralintide (CAS 2883634-40-8); AbMole: Eloralintide (LY 3841136)

Eloralintide is NOT FDA-approved or EMA-approved. It is in Phase 1/2 clinical development by Eli Lilly. This listing is for industrial and laboratory research use only. It is not medical advice, a clinical recommendation, or an approved therapy description. Always verify regulatory status, purity, and intended use with the supplier and applicable authorities before purchase or use.